# Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

> **NCT05621525** · PHASE1 · TERMINATED · sponsor: **LianBio LLC** · enrollment: 7 (actual)

## Conditions studied

- Advanced Solid Tumor
- Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BBP-398

## Key facts

- **NCT ID:** NCT05621525
- **Lead sponsor:** LianBio LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-18
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Business reason
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621525, "Phase I Study of the BBP-398 in Patients With Advance Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05621525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*